NCT00004922View on ClinicalTrials.gov

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 1999

Primary Completion Date

June 30, 2002

Study Completion Date

June 30, 2002

Conditions
Carcinoma of Unknown PrimaryNeuroendocrine CarcinomaNeuroendocrine Carcinoma of the Skin
Interventions
DRUG

irinotecan hydrochloride

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00004922 - Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter